HomeCompareSLVMF vs ABBV

SLVMF vs ABBV: Dividend Comparison 2026

SLVMF yields 1349.53% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SLVMF wins by $269284839.63M in total portfolio value
10 years
SLVMF
SLVMF
● Live price
1349.53%
Share price
$0.15
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$269284839.73M
Annual income
$235,026,052,065,859.03
Full SLVMF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — SLVMF vs ABBV

📍 SLVMF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSLVMFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SLVMF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SLVMF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SLVMF
Annual income on $10K today (after 15% tax)
$114,709.85/yr
After 10yr DRIP, annual income (after tax)
$199,772,144,255,980.16/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, SLVMF beats the other by $199,772,144,234,924.16/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SLVMF + ABBV for your $10,000?

SLVMF: 50%ABBV: 50%
100% ABBV50/50100% SLVMF
Portfolio after 10yr
$134642419.92M
Annual income
$117,513,026,045,315.39/yr
Blended yield
87.28%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SLVMF
No analyst data
Altman Z
82.5
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SLVMF buys
0
ABBV buys
0
No recent congressional trades found for SLVMF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSLVMFABBV
Forward yield1349.53%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$269284839.73M$102.3K
Annual income after 10y$235,026,052,065,859.03$24,771.77
Total dividends collected$266763063.23M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SLVMF vs ABBV ($10,000, DRIP)

YearSLVMF PortfolioSLVMF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$145,653$134,952.77$11,550$430.00+$134.1KSLVMF
2$1,992,881$1,837,032.13$13,472$627.96+$1.98MSLVMF
3$25,623,058$23,490,675.96$15,906$926.08+$25.61MSLVMF
4$309,684,527$282,267,854.29$19,071$1,382.55+$309.67MSLVMF
5$3,519,713,895$3,188,351,451.47$23,302$2,095.81+$3519.69MSLVMF
6$37,632,589,992$33,866,496,124.05$29,150$3,237.93+$37632.56MSLVMF
7$378,676,907,768$338,410,036,477.29$37,536$5,121.41+$378676.87MSLVMF
8$3,587,653,205,892$3,182,468,914,579.67$50,079$8,338.38+$3587653.16MSLVMF
9$32,017,558,563,920$28,178,769,633,615.88$69,753$14,065.80+$32017558.49MSLVMF
10$269,284,839,729,253$235,026,052,065,859.03$102,337$24,771.77+$269284839.63MSLVMF

SLVMF vs ABBV: Complete Analysis 2026

SLVMFStock

Silver Mines Limited primarily engages in the acquisition, exploration, and development of silver projects in Australia. It operates through two segments, Mining and Exploration Operations, and Agricultural Operations. The company also explores for copper, gold, lead, zinc, and polymetallic deposits. Its properties include Bowdens Silver Project, which has silver and polymetallic prospects covering an area of 1,950 square kilometers located in the Central Tablelands Region, New South Wales; the Barabolar Project consists of copper, gold, and silver prospects located in the Macquarie Arc in New South Wales; and Tuena Project with gold and silver prospects, which is located 80 kilometers south of the city of Orange in New South Wales. Silver Mines Limited was incorporated in 2004 and is based in Sydney, Australia.

Full SLVMF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this SLVMF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SLVMF vs SCHDSLVMF vs JEPISLVMF vs OSLVMF vs KOSLVMF vs MAINSLVMF vs JNJSLVMF vs MRKSLVMF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.